Garuda - Garba Rujukan Digital

Management of Resistance to Targeted Therapy in EGFR Mutational Lung Adenocarcinoma: A Case Report Armiza; Sabrina Ermayanti; Afriani
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 2 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i2.779

Advances in diagnosis and treatment have enabled a targeted therapy approach to inhibit tumor progression and provide a favorable prognosis. One of the targeted therapies in non-small cell lung cancer (NSCLC) is tyrosine kinase inhibitor (TKI) in mutations epidermal growth factor receptor (EGFR). This study aimed to present a case with the management of resistance to targeted therapy in EGFR-mutated lung adenocarcinoma. Data shows median progression-free survival patients on TKI therapy at 10 to 14 months. Progressive caused by resistance to TKI and assessed using response evaluation criteria in solid tumors (RECIST) 1.1. and confirmed by repeat biopsy. Reported a male patient aged 66 years with adenocarcinoma of the right lung EGFR deletion exon 19 mutation and received afatinib therapy for 16 months. Patients experience oligo progressive in the 13th month of therapy and systemic progression 16th month.

Management of Resistance to Targeted Therapy in EGFR Mutational Lung Adenocarcinoma: A Case Report Armiza; Sabrina Ermayanti; Afriani
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 2 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i2.779

Advances in diagnosis and treatment have enabled a targeted therapy approach to inhibit tumor progression and provide a favorable prognosis. One of the targeted therapies in non-small cell lung cancer (NSCLC) is tyrosine kinase inhibitor (TKI) in mutations epidermal growth factor receptor (EGFR). This study aimed to present a case with the management of resistance to targeted therapy in EGFR-mutated lung adenocarcinoma. Data shows median progression-free survival patients on TKI therapy at 10 to 14 months. Progressive caused by resistance to TKI and assessed using response evaluation criteria in solid tumors (RECIST) 1.1. and confirmed by repeat biopsy. Reported a male patient aged 66 years with adenocarcinoma of the right lung EGFR deletion exon 19 mutation and received afatinib therapy for 16 months. Patients experience oligo progressive in the 13th month of therapy and systemic progression 16th month.

Profil Pasien COVID-19 dengan Komorbid yang Dirawat di RSUP Dr. M. Djamil Padang Hamni Tanjung; Julizar Julizar; Sabrina Ermayanti; Deddy Herman; Liganda Endo Mahata; Syandrez Prima Putra
Jurnal Ilmu Kesehatan Indonesia Vol 4 No 1 (2023): Maret 2023
Publisher : Fakultas Kedokteran, Universitas Andalas

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.25077/jikesi.v4i1.971

Latar Belakang: Coronavirus Disease 2019 (COVID-19) yang disebabkan Severe Acute Respiratory Coronavirus-2 (SARS-CoV-2) telah menjadi perhatian dunia sejak awal ditemukan hingga saat ini. Keparahan kondisi pasien COVID-19 dengan komorbid dipengaruhi dengan berbagai faktor yang dapat meningkatkan morbiditas dan mortalitas pasien COVID-19. Objektif: Penelitian ini bertujuan untuk mengetahui profil pasien COVID-19 dengan komorbid yang dirawat di RSUP Dr. M. Djamil Padang. Metode: Jenis penelitian ini merupakan observasional deskriptif dengan pendekatan cross-sectional. Data penelitian diambil dari data rekam medis dengan teknik pengambilan total sampling pada pasien yang dirawat pada 1 Oktober sampai 31 Desember 2020. Hasil: Penelitian ini mendapatkan dari total 144 pasien, 34% pasien COVID-19 dengan komorbid merupakan kelompok usia 50-59 tahun, 50,7% berjenis kelamin laki-laki, 59,7% memiliki riwayat pendidikan tingkat menengah dan 53,5% berstatus IMT obesitas. Komorbid terbanyak yang ditemukan adalah 29,2% hipertensi dengan 73,6% pasien memiliki lebih dari satu komorbid, sebanyak 77,1% merupakan COVID-19 derajat sedang dengan 71,5% memiliki lama rawatan 14 hari atau kurang, serta 62,5% memiliki luaran COVID-19 sembuh. Kesimpulan: Penelitian ini menemukan sebagian besar pasien COVID-19 dengan komorbid yang dirawat merupakan kelompok usia tua, dengan komorbid terbanyak hipertensi, sebagian besar memiliki lebih dari satu komorbid, mengalami derajat sakit sedang dengan lama rawatan 14 hari atau kurang, dan luaran sembuh.

Indonesian Society of Respirology (ISR) Consensus Statement on Lung Cancer Screening and Early Detection in Indonesia Sita Andarini; Elisna Syahruddin; Nathaniel Aditya; Jamal Zaini; Ferry Dwi Kurniawan; Sabrina Ermayanti; Noni Novisari Soeroso; Sri Melati Munir; Andreas Infianto; Ana Rima; Ungky Agus Setyawan; Laksmi Wulandari; Haryati Haryati; Ida Ayu Jasminarti; Arif Santoso
Jurnal Respirologi Indonesia Vol 43, No 2 (2023)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v43i2.455

Lung cancer is the leading cause of mortality for all cancer globally and in Indonesia. In Indonesia, lung cancer contributes to 12.6% of death of all cancer, making it the number one cause of cancer death, and 8.6% of all cancer incidence in 2018, behind breast, cervical, and colorectal cancer. The total cases per year are expected to almost double from 30,023 in 2018 to 54,983 cases in 2040. Smoking is among the risk factors for lung cancer, after occupational/environmental risk factors, history of lung fibrosis, and family history of cancer. There was a tendency of younger smokers in Indonesia and increased lung cancer incidence and prevalence in the younger population. The median age of lung cancer in Indonesia was younger than in any country, probably due to the younger age of smoking, early onset of carcinogens, asbestos use, and environmental. Lung cancer screening is a voluntary measure to detect lung cancer in the earliest stage, to find cancer at curable disease before symptoms appear in high-risk individuals. Lung cancer early detection is strategies to find cancer earlier after symptoms appear (cough, hemoptysis, dyspnea, chest pain). Low-dose computerized tomography of the thorax (LDCT) screening has been known to reduce lung cancer mortality compared to a chest x-ray (CXR). This Indonesian Society of Respirology consensus statement was aimed to give recommendations on lung cancer screening and early diagnosis in Indonesia.

LENT Score as a Prognosis Factor for Overall Survival and Progression-Free Survival in Malignant Pleural Effusion Patients at Tertiary Hospitals in West Sumatera, Indonesia Laisa Azka; Sabrina Ermayanti; Russilawati; Irvan Medison; Deddy Herman; Fenty Anggraininy
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 6 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i6.835

Background: Malignant pleural effusion (MPE) has a variable survival rate and prognosis. The LENT score is one method for assessing survival rates in patients with MPE. This study aimed to investigate the LENT score as a prognostic factor for overall survival (OS) and progression-free survival (PFS) of patients with MPE at a tertiary hospital in West Sumatera. Methods: This study was an observational analytic study involving several tertiary hospitals in West Sumatera with a minimum observation period of 2 years. Data were collected from medical records. We used Kaplan Meier analysis to assess OS and PFS. Results: A total of 198 subjects met the inclusion criteria. Most MPE patients in this study were aged ≥60 years, male, smokers, pleural fluid lactate dehydrogenase value <1500, ECOG 1, serum NLR value <9, and high-risk cancer, namely lung cancer. The distribution of LENT scores for MPE patients was evenly distributed among the low, medium, and high-risk groups. Kaplan Meier analysis showed that the median OS based on LENT scores were 804 days, 275 days, and 161 days, respectively (log-rank test p = 0.000). The median PFS based on LENT scores were 715 days, 202 days, and 106 days, respectively (log-rank test p=0.000). The OS and PFS findings are longer than previous studies. Conclusion: Based on LENT scores, overall survival and progression-free survival MPE patients at tertiary hospitals in West Sumatera have a better prognosis compared to previous studies.

LENT Score as a Prognosis Factor for Overall Survival and Progression-Free Survival in Malignant Pleural Effusion Patients at Tertiary Hospitals in West Sumatera, Indonesia Laisa Azka; Sabrina Ermayanti; Russilawati; Irvan Medison; Deddy Herman; Fenty Anggraininy
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 6 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i6.835

Background: Malignant pleural effusion (MPE) has a variable survival rate and prognosis. The LENT score is one method for assessing survival rates in patients with MPE. This study aimed to investigate the LENT score as a prognostic factor for overall survival (OS) and progression-free survival (PFS) of patients with MPE at a tertiary hospital in West Sumatera. Methods: This study was an observational analytic study involving several tertiary hospitals in West Sumatera with a minimum observation period of 2 years. Data were collected from medical records. We used Kaplan Meier analysis to assess OS and PFS. Results: A total of 198 subjects met the inclusion criteria. Most MPE patients in this study were aged ≥60 years, male, smokers, pleural fluid lactate dehydrogenase value <1500, ECOG 1, serum NLR value <9, and high-risk cancer, namely lung cancer. The distribution of LENT scores for MPE patients was evenly distributed among the low, medium, and high-risk groups. Kaplan Meier analysis showed that the median OS based on LENT scores were 804 days, 275 days, and 161 days, respectively (log-rank test p = 0.000). The median PFS based on LENT scores were 715 days, 202 days, and 106 days, respectively (log-rank test p=0.000). The OS and PFS findings are longer than previous studies. Conclusion: Based on LENT scores, overall survival and progression-free survival MPE patients at tertiary hospitals in West Sumatera have a better prognosis compared to previous studies.

Title

Found 26 Documents
Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title Search

Found 26 Documents Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title

Found 26 Documents
Search